Low-dose Initiation of Buprenorphine/naloxone for the Management of Chronic Non-cancer Pain in Patients on Long-term Opioid Therapy: A Case Series

References

• Rudolf GD. Buprenorphine in the treatment of chronic pain. Phys Med Rehabil Clin N Am. 2020;31(2):195–12. doi:10.1016/j.pmr.2020.02.001.
   PubMed Web of Science ®Google Scholar
• Bruneau J, Ahamad K, Goyer MÈ, Poulin G, Selby P, Fischer B, Wild TC, Wood E. Management of opioid use disorders: a national clinical practice guideline. CMAJ. 2018;190(9):E247–E257. doi:10.1503/cmaj.170958.
   PubMed Web of Science ®Google Scholar
• Latif ZEH, Skjærvø I, Solli KK, Tanum L. Chronic pain among patients with an opioid use disorder. Am J Addict. 2021;30(4):366–75. doi:10.1111/ajad.13153.
   PubMed Web of Science ®Google Scholar
• MG30 chronic pain. In: ICD-11 for mortality and morbidity statistics. World Health Organization; 2023. https://icd.who.int/browse11/l-m/en#/http://id.who.int/icd/entity/132633283.
   Google Scholar
• The Canadian Pain Task Force. An action plan for pain in Canada. Ottawa (ON): Health Canada; 2021. https://www.canada.ca/content/dam/hc-sc/documents/corporate/about-health-canada/public-engagement/external-advisory-bodies/ernese-pain-task-force/report-2021-rapport/report-rapport-2021-eng.pdf.
   Google Scholar
• Opioids (Canadian Drug Summary). Canadian centre on substance use and addiction. Ottawa (ON); [accessed 2023 Apr 11]. https://ccsa.ca/opioids-canadian-drug-summary.
   Google Scholar
• Spreen LA, Dittmar EN, Quirk KC, Smith MA. Buprenorphine initiation strategies for opioid use disorder and pain management: a systematic review. Pharmacotherapy. 2022;42(5):411–27. doi:10.1002/phar.2676.
   PubMed Web of Science ®Google Scholar
• Robbins JL, Englander H, Gregg J. Buprenorphine microdose induction for the management of prescription opioid dependence. J Am Board Fam Med. 2021;34(Supplement):S141–S146. doi:10.3122/jabfm.2021.S1.200236.
   PubMedGoogle Scholar
• Case AA, Kullgren J, Anwar S, Pedraza S, Davis MP. Treating chronic pain with buprenorphine-the practical guide. Curr Treat Options Oncol. 2021;22(12):116. doi:10.1007/s11864-021-00910-8.
   PubMed Web of Science ®Google Scholar
• Chen KY, Chen L, Mao J. Buprenorphine–naloxone therapy in pain management. Anesthesiology. 2014;120(5):1262–74. doi:10.1097/ALN.0000000000000170.
   PubMed Web of Science ®Google Scholar
• Suboxone. Indivior UK Limited. The drug and Health Product Register. Health Canada; 2003. Revised, October 26, 2021 [accessed 2023 Nov 12]. https://pdf.hres.ca/dpd_pm/00041002.PDF
   Google Scholar
• Suboxone®. Highlights of prescribing information. Indivior UK Limited; 2003 [accessed 2023 Nov 12]. https://www.suboxone.com/pdfs/prescribing-information.pdf
   Google Scholar
• Korownyk C, Perry D, Ton J, Kolber MR, Garrison S, Thomas B, Allan GM, Bateman C, de Queiroz R, Kennedy D, et al. Managing opioid use disorder in primary care: PEER simplified guideline. Can Fam Physician. 2019;65(5):321–30.
   PubMed Web of Science ®Google Scholar
• Weiss RD, Potter JS, Griffin ML, McHugh RK, Haller D, Jacobs P, Cardin II J, Fischer D, Rosen KD. Reasons for opioid use among patients with dependence on prescription opioids: the role of chronic pain. J Subst Abuse Treat. 2014;47(2):140–45. doi:10.1016/j.jsat.2014.03.004.
   PubMed Web of Science ®Google Scholar
• Rieb LM, Norman WV, Martin RE, Berkowitz J, Wood E, McNeil R, Milloy MJ. Withdrawal-associated injury site pain (WISP): a descriptive case series of an opioid cessation phenomenon. PAIN. 2016;157(12):2865. doi:10.1097/j.pain.0000000000000710.
   PubMed Web of Science ®Google Scholar
• Crawley A, LeBras M, Regier L. OPIOID TAPERING: choosing an approach. RxFiles; Published 2022 May [accessed 2023 Apr 11]. https://www.rxfiles.ca/RxFiles/uploads/documents/members/Opioid-Tapering-Strategies.pdf.
   Google Scholar
• Magnan EM, Tancredi DJ, Xing G, Agnoli A, Jerant A, Fenton JJ. Association between opioid tapering and subsequent health care use, medication adherence, and chronic condition control. JAMA Network Open. 2023;6(2):e2255101. doi:10.1001/jamanetworkopen.2022.55101.
   PubMed Web of Science ®Google Scholar
• Weimer MB, Fiellin DA. Low‐ and very low‐dose buprenorphine induction: new(ish) uses for an old(ish) medication? Addiction. 2022;117(6):1507–09. doi:10.1111/add.15799.
   PubMed Web of Science ®Google Scholar
• Leyde S, Suen L, Pratt L, DeFries T. Transition from oxycodone to buprenorphine/naloxone in a hospitalized patient with sickle cell disease: a case report. J Gen Intern Med. 2022;37(5):1281–85. doi:10.1007/s11606-021-07295-2.
   PubMed Web of Science ®Google Scholar
• Jasmine Silva M, Coffee Z, Goza J, Rumrill K. Microinduction to buprenorphine from methadone for chronic pain: outpatient protocol with case examples. J Pain Palliat Care Pharmacother. 2022;36(1):40–48. doi:10.1080/15360288.2022.2049422.
   PubMed Web of Science ®Google Scholar
• Kornfeld H, Reetz H. Transdermal buprenorphine, opioid rotation to sublingual buprenorphine, and the avoidance of precipitated withdrawal: a review of the literature and demonstration in three chronic pain patients treated with butrans. Am J Ther. 2015;22(3):199–205. doi:10.1097/MJT.0b013e31828bfb6e.
   PubMed Web of Science ®Google Scholar
• Sandhu R, Zivanovic R, Klaire S, Nikoo M, Rozylo J, Azar P. Buprenorphine/naloxone induction for treatment of acute on chronic pain using a micro-dosing regimen: a case report. Can J Pain Rev Can Douleur. 2019;3(1):79–84. doi:10.1080/24740527.2019.1599279.
   PubMed Web of Science ®Google Scholar
• Becker WC, Frank JW, Edens EL. Switching from high-dose, long-term opioids to buprenorphine: a case series. Ann Intern Med. 2020;173(1):70–71. doi:10.7326/L19-0725.
   PubMed Web of Science ®Google Scholar
• Crum IT, Meyer Karre VM, Balasanova AA. Transitioning from intrathecal hydromorphone to sublingual buprenorphine-naloxone through microdosing: a case report. AA Pract. 2020;14(11):e01316. doi:10.1213/XAA.0000000000001316.
   Google Scholar
• Lee DS, Hann JE, Klaire SS, Nikoo M, Negraeff MD, Rezazadeh-Azar P. Rapid induction of buprenorphine/naloxone for chronic pain using a microdosing regimen: a case report. AA Pract. 2020;14(2):44–47. doi:10.1213/XAA.0000000000001138.
   Google Scholar
• Tara A, Acampora G, Wang J, De Sousa K, Zhang Y. Facilitating discontinuation of intravenous opioids by -concurrent use of sublingual buprenorphine with rapid microdosing -induction: a pain management case study. J Opioid Manage. 2021;17(7):153–58. doi:10.5055/jom.2021.0652.
   PubMedGoogle Scholar
• MacAusland-Berg J, Wiebe A, Marwah R, Halpape K. Successful conversion from butorphanol nasal spray to buprenorphine/naloxone using a low-dose regimen to assist with opioid tapering in the setting of chronic pain and migraine management in an older adult patient: a case report. Can J Pain Rev Can Douleur. 2022;6(1):135–41. doi:10.1080/24740527.2022.2090911.
   PubMed Web of Science ®Google Scholar
• Halpape K, Jorgenson D, Ahmed A, Kizlyk K, Landry E, Marwah R, Raiche T, Wiebe A. Pharmacist-led strategy to address the opioid crisis: the Medication Assessment Centre Interprofessional Opioid Pain Service (MAC iOPS). Can Pharm J Rev Pharm Can. 2021;155:171516352110459. doi:10.1177/17151635211045950.
   Google Scholar
• Jorgenson D, Halpape K. Evaluation of a pharmacist-led interprofessional chronic pain clinic in Canada. Can Pharm J/Revue Des Pharmaciens du Canada. 2023;156(5):265–71. doi:10.1177/17151635231188334.
   Google Scholar
• Patel P, Dunham K, Lee K. Buprenorphine/naloxone microdosing: the ernese method. A brief summary for primary care clinicians. Canadian Mental Health Association and Thames Valley Family Health Team; Published 2019 Sep [accessed 2023 Feb 13]. https://www.metaphi.ca/wp-content/uploads/Guide_Microdosing.pdf.
   Google Scholar
• Busner J, Targum SD. The clinical global impressions scale: applying a research tool in clinical practice. Psychiatry (Edgmont). 2007;4:28–37.
   PubMedGoogle Scholar
• Kroenke K, Spitzer RL, Williams JBW. The PHQ-9. J Gen Intern Med. 2001;16(9):606–13. doi:10.1046/j.1525-1497.2001.016009606.x.
   PubMed Web of Science ®Google Scholar
• Spitzer RL, Kroenke K, Williams JBW, Löwe B. A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med. 2006;166(10):1092–97. doi:10.1001/archinte.166.10.1092.
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Washington D.C.: American Psychiatric Association; 2013. doi:10.1176/appi.books.9780890425596.
   Google Scholar
• Sullivan MJL, Bishop SR, Pivik J. The pain catastrophizing scale: development and validation. Psychol Assess. 1995;7(4):524–32. doi:10.1037/1040-3590.7.4.524.
   Web of Science ®Google Scholar
• Greenhalgh J, Gooding K, Gibbons E, Dalkin S, Wright J, Valderas J, Black N. How do patient reported outcome measures (PROMs) support clinician-patient communication and patient care? A realist synthesis. J Patient-Rep Outcomes. 2018;2(1):42. doi:10.1186/s41687-018-0061-6.
   PubMedGoogle Scholar
• Vowles KE, McEntee ML, Julnes PS, Frohe T, Ney JP, van der Goes DN. Rates of opioid misuse, abuse, and addiction in chronic pain: a systematic review and data synthesis. PAIN. 2015;156(4):569. doi:10.1097/01.j.pain.0000460357.01998.f1.
   PubMed Web of Science ®Google Scholar